As ALS Awareness Month comes to a close, it’s a good time to reflect on what we’ve accomplished, and perhaps more importantly, to find ways to both sustain and build upon our momentum as we search and fight for cures. For the past month, members of the ALS…

The Foundation for the National Institutes of Health (FNIH) is launching a public-private partnership to generate the largest openly available data platform in amyotrophic lateral sclerosis (ALS) research, with the goal of accelerating the diagnosis and treatment of the progressive neurodegenerative disease. This five-year initiative will be conducted through…

A new documentary about I AM ALS and the “revolutionary movement” begun by the organization’s founders — which will stream globally on May 28 — is seeking to advance awareness of amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders while inspiring others to fight for change. Called “For…

As I read my daily emails and text messages, I think of my condition and what ALS Awareness Month means to me. How does it make me feel? What can I do to enhance the effects of this special month? Like the Ice Bucket Challenge, what is its…

Nature calms me and nourishes my soul amid the challenges of giving care to my husband, Todd, who has ALS. A few days ago, I walked down our country road, listening to singing birds and taking in spring’s beauty. I admired signs of new life — budding green leaves…

People with amyotrophic lateral sclerosis (ALS) who continued treatment with NurOwn (debamestrocel) after completing a Phase 3 trial experienced additional benefits with extended treatment, data show. The findings come from 10 adults who received up to six additional doses of NurOwn over nearly one year in an expanded…

By taking advantage of a molecular interaction between the disease-related protein TDP-43 and another, innocuous protein, scientists have found a novel strategy that potentially may be used as a treatment for amyotrophic lateral sclerosis (ALS). “Importantly, this interaction could be key to unlocking a treatment not just for ALS…

Biogen and Ionis Pharmaceuticals have decided to terminate the development of BIIB105, their experimental treatment for amyotrophic lateral sclerosis (ALS), based on data from a Phase 1/2 clinical trial. The therapy resulted in no significant clinical benefit compared with a placebo after six months, and data from…

A new amyotrophic lateral sclerosis (ALS) assessment called delta-FS — defined as the rate of decline over time in the ALS Functional Rating Scale-Revised (ALSFRS-R) — has been proposed as an attractive, easily obtainable tool to monitor disease severity and predict patient prognosis. The assessment also could be used…

My son joined middle school track this year, and after a few days of practice, my husband, Todd, asked how it was going. “I’m not a long-distance runner,” he said. “I don’t know how to pace myself.” “I was no good for any distance, either,” Todd said. “I ran…